Please complete the CAPTCHA to continue
A concise factual answer block for searchers comparing this professional profile.
Maria Karasarides, Ph.D. is listed as Science | Drug Development | Healthcare Innovation at Primary Venture Partners, a company with 58 employees, based in Boston, Massachusetts, United States. AeroLeads shows a matched LinkedIn profile for Maria Karasarides, Ph.D..
Maria Karasarides, Ph.D. previously worked as Expert at Primary Venture Partners and Scientific Advisory Board at Revivemed. Maria Karasarides, Ph.D. holds Executive Education, Leadership And Strategy In Pharmaceuticals And Biotech from Harvard Business School.
This section adds company-level context without repeating Maria Karasarides, Ph.D.'s masked contact details.
Review company-level records connected to Maria Karasarides, Ph.D. before choosing the right outreach path.
As a scientist and drug developer, my mission is to deliver value to patients and innovation to the marketplace. I develop strategy and drive transformational change by building high performance teams and uniting people to share a vision for shaping the future of healthcare. I am passionate about scientific discovery, improving the patient experience and delivering clinically meaningful solutions to real-world problems. I create value by translating science and technology into innovative products and practices to improve the lives of patients and ignite business growth. With a proven track record in leading biopharma organizations, my experience spans early- and late-stage drug development, pipeline strategy, registrational trial execution, drug launch, and AI powered precision medicine. Bridging strategy and deliberate execution to business outcomes, I consistently deliver accelerated pipeline growth and successfully lead teams to achieve growth, prioritize the patient needs with equity and inclusivity, and maintain focus in times of uncertainty. My roots in academic science were anchored in the Ras-Raf-MAPK pathway and led me, in 2004, to validate B-Raf as a therapeutic target in melanoma. In 2006, I joined the pharmaceutical sector and within a few years witnessed the impact of novel immune therapies on the lives of patients. Through the development and approval of Yervoy® we delivered the first cancer immunotherapy that would revolutionize cancer treatment paradigms and would enliven our hope for cancer cures. During the past decade, I contributed to the late-stage development and approval of the PD-L1 checkpoint inhibitor Imfinzi® and led numerous early-stage clinical programs designed to maximize the efficacy of checkpoint blockade through novel combinations or bring forward novel immunotherapy targets and therapeutic modalities, including CD3 and CD28 directed bispecific antibodies. As grateful as I am for the progress we made, I am deeply aware that most cancer patients treated in real-world practice do not experience their own personal cure. Making real progress in the coming decade will demand the integration of predictive technologies to improve drug development paradigms, a deliberate focus on precision medicine, and innovation strategies that meaningfully improve patient care. Mindful of this, together with my collaborators I founded GUIDE.MRD, a public private partnership that will advance our confidence in ctDNA diagnostic assays and aim to develop minimal residual disease (MRD) as a clinical decision tool for solid tumor malignancies.
Company context helps verify the profile and gives searchers a useful next step.
A career timeline built from the work history available for this profile.
Primary is NYC's premier early-stage venture firm working alongside founders and visionaries to build unicorns companies that bring innovation to the marketplace. As an Expert, I provide strategic advice and guidance to the investment team and founders within the Primary portfolio and their broader network.
"Revolutionizing Precision Medicine with the Power of AI and Metabolomics"
United States
Led a multi-focal team to deliver the oncology early asset pipeline through proof-of-concept governance decisions and oversaw the diagnostic readiness strategy for oncology launches. Piloted the oncology “medical innovation” strategy and delivered pilot programs to address gaps that impede product use in clinical practice and accelerate clinical.
Greater New York City Area
Led the cross-functional development teams for the solid tumor early development oncology pipeline. Accountable for development program strategy, IND submissions, drug supply planning, program budget and program governance. - Led the early development programs of the oncology pipeline including REGN3767 (Lag-3 and iPET Lag-3), REGN4659 (CTLA-4), REGN6569.
Drove the oncology novel-novel combinations development program in collaboration with peer pharma companies to identify accelerated approval opportunities for durvaluab and tremelimumab as part of an enterprise objective to drive differentiated growth. - Headed the immuno-oncology external combinations team responsible for the development of novel.
Boston, MA
Led the clinical development of an inducible IL-12 gene therapy in glioma and melanoma and drove protocols, investigator brochures, steering committees, annual reports & publication plans. Delivered the Ph1 First-in-Human glioma protocol and achieved a successful review by the NIH Recombinant DNA Advisory Committee (RAC) and subsequently FDA clearance to.
Cambridge, MA
Contributed across the cross-functional matrix to provide enabling support for the MM-398 (nanoliposomal irinotecan) development program. Provided direct project support in the areas of NDA preparation, Ph3 data package readiness, secondary analysis planning, package insert simulation, medication guide scenario planning, and ODAC preparedness. MM-398.
Cambridge, MA
Initiated the effort to establish the Medical Affairs function and ensure late stage development and commercialization readiness for Saridegib (IPI-926, oral Hedgehog inhibitor), Retaspimycin HCL (IPI-504, HSP90 inhibitor) and Eganelisib (IPI-549, PI3K-gamma). Multiple Ph2 trials failed their endpoints in 2012 and triggered a financial restructure and.
Plainsboro, NJ
Led the US Medical Affairs team and the cross-functional matrix to advance brivanib alaninate, an investigational FGF/VEGF tyrosine kinase inhibitor, through Ph3 development, BLA filing, launch readiness and commercialization. Accelerated the HCC patient journey framework and established the US “Liver Health” campaign, an enterprise partnership to improve.
Accountable for the global medical strategy to support the development of brivanib alaninate. Drove the integration of clinical development and commercialization priorities and devised the global strategy to advance pivotal data disclosure, unbranded liver disease strategy, and engagement of prioritized markets to achieve trial enrollment and launch.
Plainsboro, NJ
Led the execution of the YervoyTM (ipilimumab) US launch strategy. YervoyTM (ipilimumab), an anti-CTLA-4 monoclonal antibody, was the first FDA approved checkpoint inhibitor for the treatment of malignant melanoma. Headed the ipilimumab data generation strategy and oversaw the Investigator Sponsored Trial program. Drove secondary analyses branching from.
Worcester, Massachusetts, United States
Post Doctoral Fellowship, Roger Davis, Ph.D. LaboratoryConducted primary research on JNK / 38 signaling in cancer development and metastasis. Elucidated the cooperativity of JNK and PTEN on the development of prostate adenocarcinoma using inducible mouse models.
Greater London, England, United Kingdom
Post Doctoral Fellowship, Richard Marais, Ph.D. LaboratoryConducted primary research on oncogenic B-RAF signaling. Discovered siRNA mediated B-RAF silencing results in cellular apoptosis and led the pre-clinical validation of B-RAF as a therapeutic target in melanoma. Discovered TNFa/ NFkB mediated resistance of B-RAF inhibition and established a basis for.
Other employees you can reach at primary.vc. View company contacts for 58 employees →
Pooja Radia
Colleague at Primary Venture PartnersNew York, New York, United States, United States
View →
PC
Peter Campbell
Colleague at Primary Venture PartnersNew York, New York, United States, United States
View →
ZF
Zach Fredericks
Colleague at Primary Venture PartnersNew York, New York, United States, United States
View →
MD
Mark Diffley
Colleague at Primary Venture PartnersNew York, New York, United States, United States
View →
NP
Ndayambaje Pascal
Colleague at Primary Venture PartnersKigali, Kigali City, Rwanda, Rwanda
View →
BO
Bishwanath Oraon
Colleague at Primary Venture PartnersDelhi, India, India
View →
CH
Charles Holley
Colleague at Primary Venture PartnersNew York, New York, United States, United States
View →
JM
Jessica Miller
Colleague at Primary Venture PartnersNew York, New York, United States, United States
View →
JP
Juliana Pyo
Colleague at Primary Venture PartnersNew York, New York, United States, United States
View →
AC
Amber Cohon
Colleague at Primary Venture PartnersNew York, New York, United States, United States
View →
Quick answers generated from the profile data available on this page.
Maria Karasarides, Ph.D. works for Primary Venture Partners.
Maria Karasarides, Ph.D. is listed as Science | Drug Development | Healthcare Innovation at Primary Venture Partners.
Maria Karasarides, Ph.D. is based in Boston, Massachusetts, United States while working with Primary Venture Partners.
Maria Karasarides, Ph.D. has worked for Primary Venture Partners, Revivemed, Picture Health, Bristol Myers Squibb, and Regeneron Pharmaceuticals, Inc..
Maria Karasarides, Ph.D.'s colleagues at Primary Venture Partners include Pooja Radia, Peter Campbell, Zach Fredericks, Mark Diffley, and Ndayambaje Pascal.
You can use AeroLeads to view verified contact signals for Maria Karasarides, Ph.D. at Primary Venture Partners, including work email, phone, and LinkedIn data when available.
Maria Karasarides, Ph.D. holds Executive Education, Leadership And Strategy In Pharmaceuticals And Biotech from Harvard Business School.
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial Search contacts